Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Biogen Inc. (BIIB) - free report >>
Merck & Co., Inc. (MRK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Inc. (BIIB) - free report >>
Merck & Co., Inc. (MRK) - free report >>
Image: Bigstock
Biogen's Humira Biosimilar Imraldi Gets Approval in EU
Biogen Inc. (BIIB - Free Report) announced that its biosimilar version of AbbVie, Inc.’s (ABBV - Free Report) top-selling blockbuster drug, Humira has been approved by the European Commission. The biosimilar will be marketed by the trade name of Imraldi.
Imraldi (or SB5) will be used for a whole range of indications including rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa and non-infectious uveitis.
We remind investors that the biosimilar was granted a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) in June this year.
Biogen has a joint venture with Samsung BioLogics for biosimilars. Samsung Bioepis, the joint venture between the two companies, already marketsa couple of biosimilars in the EU – Flixabi (a biosimilar referencing J&J/Merck & Co., Inc.’s [(MRK - Free Report) ] Remicade) and Benepali (a biosimilar referencing Amgen/Pfizer’s Enbrel). This makes Imraldi the third anti-TNF biosimilar from Biogen to receive a marketing authorization in the EU.
Benepali is doing quite well, generating sales of $154 million in the first half of 2017 while Flixabi recorded sales of $2.5 million in the same period.
We note that earlier this year, Amgen, Inc. (AMGN - Free Report) gained EU approval for Amgevita, its biosimilar version of Humira.
Biogen’s shares have risen 0.6% this year so far while the industry recorded an increase of 7.9%.
Biogen carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>